Australia Signs Manufacturing Agreement With AstraZeneca For The Oxford COVID-19 Vaccine

Australia entered a manufacturing deal for a potential COVID-19 Vaccine candidate that is being developed by AstraZeneca. According to the terms of the agreement, all Australians will receive the COVID-19 vaccine once the Oxford University trials are successful.

Australia to vaccinate all its population with Oxford vaccine

Scott Morrison the Prime Minister of Australia indicated that the Oxford University trial is already in the third phase but there is still a need for more work to prove the viability of the vaccine. Morrison added that should the trials prove to be safe and successful they will manufacture and supply the vaccine and avail it to all the 25 million Australians for free. Although the premier suggested that the vaccine they will manufacture will be shared with neighbouring countries he however offered little details on the same.

The Prime Minister indicated that the vaccine could be available as early as next year should trial be successful as manufacturing will require a few more months. Morrison said that the vaccine could be mandatory for all Australians but the government is currently forming policy on the same.

What is AstraZeneca Oxford vaccine for coronavirus

AstraZeneca and Oxford University are developing the COVID-19 vaccine which has so far been promising. The COVID-19 vaccine candidate is among the five promising that are in advanced phases of clinical studies and various countries are already trying to secure supplies for their citizens. The SARS-CoV-2 vaccine candidate called “ChAdOxl nCoV-19” has demonstrated immune response in humans without any side effects.

The vaccine employs the adenovirus to carry the gene for the coronavirus spike protein in human subjects. Human cells will then express the gene and produce significant SARS-CoV-2 spike proteins evoking the production of antibodies.

However, it has not been ascertained fully that the vaccine can protect against the virus and it has to successfully go through the third phase trials with results expected at the end of this year. Also, it is yet to be tested on vulnerable groups and trials so far have been on young, healthy subjects.

By reading our website you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook or chat. We do not advise any reader to take any specific action. Our releases are for informational and educational purposes only. Never invest purely based on our articles. Gains mentioned on our website, twitter, Facebook, and on our website may be based on EOD or intraday data. We may be compensated for the production, release, and awareness of this article. We will disclose any and all compensation on the article page. This publication and its owner never hold positions in the securities mentioned in our articles. Our information may contain Forward-Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site. The information in our disclaimers is subject to change at any time without notice. We are not held liable or responsible for the information in press releases issued by the companies discussed in these write-ups. Please do your own due diligence